Paradoxes in the reporting of Covid19 vaccine effectiveness: Why current studies (for or against vaccination) cannot be trusted and what we can do about it
On 14 Sep, 2021 By admin 0 Comments
COVID19
Dr Peter McCullough On Covid19: Treatment, Vaccines & A Dire Warning For New Zealand
On 27 Aug, 2021 By admin 0 Comments
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
On 25 Aug, 2021 By admin 0 Comments
August, 2021
Abstract
Background: Reports of waning vaccine-induced immunity against COVID-19 have begun to surface. With that, the comparable long-term protection conferred by previous infection with SARS-CoV-2 remains unclear.
The Economic Effect of the COVID-19 Lockdown in the United States: Was the Cure Worse than the Disease?
On 23 Aug, 2021 By admin 0 Comments
May, 2021
Abstract
COVID-19 is an ongoing global outbreak of coronavirus disease 2019, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern on January 30, 2020; and a pandemic on March 11, 2020.
Impact of the COVID-19 Pandemic and Policy Responses on Excess Mortality
On 23 Aug, 2021 By admin 0 Comments
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
On 23 Aug, 2021 By admin 0 Comments
August, 2021
Abstract
Background:
Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.
Areas of uncertainty:
We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.
Data sources:
Dr. David Martin on Patent System and Over 5,000 Corona Virus Patents
On 20 Aug, 2021 By admin 0 Comments
Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?
On 13 Aug, 2021 By admin 0 Comments
August, 2021
Highlights
- Infection-enhancing antibodies have been detected in symptomatic Covid-19
- Antibody dependent enhancement (ADE) is a potential concern for vaccines
- Enhancing antibodies recognize both the Wuhan strain and Delta variants
- ADE of Delta variants is a potential risk for current vaccines
- Vaccine formulations lacking ADE epitope are suggested
Abstract
Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis
On 13 Aug, 2021 By admin 0 Comments
A TALE OF TWO SCIENTIFIC PARADIGMS: CONFLICTING SCIENTIFIC OPINIONS ON WHAT “FOLLOWING THE SCIENCE” MEANS FOR SARS-COV-2 AND THE COVID-19 PANDEMIC
On 12 Aug, 2021 By admin 0 Comments
August, 2021
DSA ADS Course - 2021
COVID19, Public Policy, Health Policy, Modeling, Model-driven Science, Empirically-driven Science, Lockdowns, Non-pharmaceutical Interventions, NPIs
Discuss 2 paradigms: Model-driven Science vs. Empirically-driven Science